New allergy pill aims to clear stuffy noses in asthma patients
NCT ID NCT07168473
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This phase 3 trial tests whether a new drug called DW1807 works better than another drug (DW1807-R2) for people with year-round allergic rhinitis who also have asthma. About 274 adults will take one of the two drugs daily for 4 weeks. The main goal is to see if DW1807 improves nasal symptoms like stuffiness and sneezing more than the comparator.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- DW1807 (experimental drug) and DW1807-R2 (active comparator drug)
- What this could lead to
- If DW1807 works better, it could offer a new treatment option for people with both year-round allergies and asthma, easing nasal symptoms.
- What could go wrong
- This is a short 4-week study with 274 participants, so results may not apply long-term or to everyone. The drug may not prove superior to the comparator.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTHMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Konkuk University Medical Center
RECRUITINGSeoul, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can tracking severe asthma over time unlock better treatments?
- Can pressurized breathing boost mucus clearance in lung disease?
- Can a simple breathing test unlock the secrets of chronic cough?
- Can a Breath-Activated inhaler match the standard for asthma control?
- Can a School-Home program tame childhood asthma?
- Could everyday supplements shield your lungs?